PFE logo

PFE
Pfizer Inc

105,114
Mkt Cap
$140.77B
Volume
0.00
52W High
$29.17
52W Low
$20.92
PE Ratio
13.17
PFE Fundamentals
50D MA
$24.88
Beta
0.42
Avg. Volume
52.42M
EPS (Annual)
$1.41
P/B
1.59
Rev/Employee
$785,518.52
Loading...
Loading...
News
all
press releases
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
Zacks·15h ago
News Placeholder
More News
News Placeholder
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Zacks·17h ago
News Placeholder
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Zacks·17h ago
News Placeholder
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc...
Business Wire·2d ago
News Placeholder
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Zacks·2d ago
News Placeholder
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Zacks·3d ago
News Placeholder
Will BMY's Growth Portfolio Drive Third-Quarter Results?
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
Zacks·4d ago
News Placeholder
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.
Zacks·5d ago
News Placeholder
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Zacks·5d ago
News Placeholder
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Zacks·5d ago

Latest PFE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.